LYS241 subcutaneous / Lys Therapeutics - LARVOL DELTA

Lys Therapeutics Raises More Than €25 Million to Advance LYS241 Toward Clinical Development in Neurology (PRNewswire) - "The proceeds will support completion of regulatory studies, manufacturing readiness and the clinical entry of LYS241 through a biomarker-rich Phase 1a/1b program. The planned program is expected to include healthy volunteer cohorts and indication-specific patient cohorts designed to assess safety, pharmacokinetics and early proof-of-biology signals across priority neurological indications....Recent preclinical data support the potential of LYS241 to address BBB dysfunction, neuroinflammation and neurodegenerative progression in Parkinson's disease. In synucleinopathies, including multiple system atrophy, additional preclinical data further support the relevance of the approach."

Financing • Preclinical • Ischemic stroke • Multiple System Atrophy • Parkinson's Disease